Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis

This study is ongoing, but not recruiting participants.

Sponsored by:	Stanford University
Information provided by:	Stanford University
ClinicalTrials.gov Identifier:	NCT00185991

Purpose

To compare once daily versus 8 hour dosing of gentamicin for the treatment of chorioamnionitis.

Condition	Intervention
Chorioamnionitis	Drug: gentamicin

Drug Information available for: Gentamicins

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Efficacy Study
Official Title:	Comparison of Once Daily Versus 8 Hour Dosing of Gentamicin for the Treatment of Intrapartum Chorioamnionitis

Further study details as provided by Stanford University:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:

Eligibility

Criteria

Inclusion Criteria::

clinical diagnosis of chorioamnionitis
 Exclusion Criteria:- maternal renal disease, intrauterine fetal death, allergy to gentamicin

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00185991

Locations

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Yasser Yehia El-Sayed

Stanford University

More Information

Study ID Numbers:	80104
Study First Received:	September 12, 2005
Last Updated:	November 6, 2008
ClinicalTrials.gov Identifier:	NCT00185991
Health Authority:	United States: Institutional Review Board

Study placed in the following topic categories:

Fetal Diseases
Pregnancy Complications
Gentamicins
Obstetric Labor Complications

Rupture
Chorioamnionitis
Fetal Membranes, Premature Rupture

Additional relevant MeSH terms:

Placenta Diseases
Protein Synthesis Inhibitors
Anti-Infective Agents
Anti-Bacterial Agents

Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009